The GLP-1 receptor agonist exenatide may be a better alternative to insulin for the management of cystic fibrosis-related diabetes (CFRD), a pilot study carried out by respiratory physicians and endocrinologists in South Australia suggests. In a study involving six young people with CF, pancreatic exocrine insufficiency and impaired glucose tolerance (IGT), they found that a ...
GLP-1 drug could be better alternative to insulin for CF-related diabetes
By Michael Woodhead
9 Oct 2018